KRAS/NRAS/BRAF mutations are associated with poor prognosis of patients with CRC [50, 51], while TNM staging prediction systems and markers such as CEA play an important role in monitoring the prognosis of gastrointestinal cancer [52, 53]. This evidence concerns the gene NRAS and colorectal carcinoma.